Jason Gotlib MD, MS

Jason Gotlib, MD, MS, is Professor of Medicine in the Division of Hematology at the Stanford University School of Medicine/Stanford Cancer Institute.

Dr. Gotlib completed medical school and his internal medicine and hematology/oncology fellowship training at Stanford, where he also earned a Master’s degree in clinical epidemiology.

Dr. Gotlib’s research focus is clinical and translational evaluation of novel therapies for myeloproliferative neoplasms, with a focus on KIT inhibitors for systemic mastocytosis (SM). He has authored more than 250 research articles, chapters, and reviews that have been published in journals including Blood, Journal of Clinical Oncology, Nature Medicine, and The New England Journal of Medicine.

Dr. Gotlib led the clinical development of midostaurin and avapritinib for patients with advanced SM, as well as response criteria for these diseases which are used by regulatory agencies for drug approval. In 2019, he was awarded the European Competence Network on Mastocytosis (ECNM) Medal as Researcher of the Year for the development of KIT-targeting therapies in advanced SM.

Dr. Gotlib currently serves as President of the American Initiative in Mast Cell Diseases (AIM). He also is actively involved with the American Society of Hematology (ASH), for which he has served as Editor-in-Chief of ASH’s The Hematologist, the Educational Co-Chair for the 2019 ASH Annual Meeting, and the Podcast Editor for Blood.

Dr. Gotlib is Vice-Chair of the NCCN Myeloproliferative Neoplasms Panel and led the development of the NCCN Guidelines® for Systemic Mastocytosis. He also serves as a member of the NCCN Chronic Myeloid Leukemia Panel.